BOLT
ANALYST COVERAGE8 analysts
HOLD
-12.9%downside to target
L $1.00
Med $4.00consensus
H $7.00
Buy
338%
Hold
563%
3 Buy (38%)5 Hold (63%)0 Sell (-1%)
Full report →
PRICE
Prev Close
4.61
Open
4.67
Day Range4.50 – 4.99
4.50
4.99
52W Range3.91 – 7.35
3.91
7.35
20% of range
VOLUME & SIZE
Avg Volume
25.1K
FUNDAMENTALS
P/E Ratio
-0.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.84
Market-like
TECHNICAL
RSI (14)
35
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18

BOLT News

About

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Justin KenkelSenior Principal Scientist
William QuinnChief Executive Officer, Chief Financial Officer, President, Secretary & Director
Michael N. AlonsoSenior Vice President of Research
Grant YonehiroChief Operating Officer & Chief Business Officer
Sarah NemecSenior Vice President of Finance & Principal Accounting Officer